Find out more about us and our portfolio companies

Series A financing led by Insight Partners and Medical Excellence Capital, with M Ventures and Pfizer Ventures joining as co-lead investors, alongside existing investors, NFX and 2048 Ventures.

FDA IND clearance enables TwoStep to initiate a first-in-human Phase 1 trial of lead peptide-drug conjugate program TS-104.

SANTA BARBARA, Calif.-Quintessent, an innovator in resilient and low-cost AI datacenter optical interconnect products, today announced it has raised $40 million in an oversubscribed Series A investment round. Quintessent also announced the start of customer sampling of its single-chip quantum dot-based DWDM comb laser – a new class of light source designed to simplify optical connectivity for rapidly scaling AI clusters.